NasdaqGM:NAMSBiotechs
NewAmsterdam Pharma (NAMS): Losses Worsen by 52% Annually as Revenue Forecasts Outpace Market
NewAmsterdam Pharma (NasdaqGM:NAMS) remains unprofitable, with net losses worsening at an average annual rate of 52% over the past five years. While the company is forecast to stay in the red for at least the next three years, revenue is expected to surge by 59.1% per year, outpacing the broader US market’s 10.5% annual growth. Despite its stock trading below the estimated fair value of $69.50, investors should note share dilution over the past year and ongoing profitability challenges even...